In this current study, PBMCs combined with anti-BTLA plus anti-CTLA-4 or anti-PD-1 Ab had significant tumor-killing effects on the PTX-pretreated tumor cells (Figure 5F,G) through activation of T cells by the BTLA blockade (Figure 6). Here, CTLA4 is linked to neoplasm.